DE69635305D1 - Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma - Google Patents

Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma

Info

Publication number: DE69635305D1
Authority: DE; Germany
Prior art keywords: interleukin; antibody; medicament; preparation; asthma
Prior art date: 1995-08-24
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69635305T

Other languages

English (en)

Other versions

DE69635305T2 (de

Inventor

Clifford Levitt

W Lee Maloy

U Kari

Nicolas Nicolaides

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ligand Pharmaceuticals Inc

Original Assignee

Genaera Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-24

Filing date

1996-08-23

Publication date

2006-03-02

1996-08-23 Application filed by Genaera Corp filed Critical Genaera Corp

2006-03-02 Publication of DE69635305D1 publication Critical patent/DE69635305D1/de

2006-07-06 Application granted granted Critical

2006-07-06 Publication of DE69635305T2 publication Critical patent/DE69635305T2/de

2016-08-24 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5425—IL-9
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Immunology (AREA)
Epidemiology (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Zoology (AREA)
Cell Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines Containing Plant Substances (AREA)

DE69635305T 1995-08-24 1996-08-23 Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma Expired - Lifetime DE69635305T2 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US276595P	1995-08-24	1995-08-24
US2765P		1995-08-24
US2380096P	1996-08-06	1996-08-06
US23800P		1996-08-06
PCT/US1996/012757 WO1997008321A1 (en)	1995-08-24	1996-08-23	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders

Publications (2)

Publication Number	Publication Date
DE69635305D1 true DE69635305D1 (de)	2006-03-02
DE69635305T2 DE69635305T2 (de)	2006-07-06

Family

ID=26670837

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DE69638281T Expired - Lifetime DE69638281D1 (de)	1995-08-24	1996-08-23	Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen
DE69635305T Expired - Lifetime DE69635305T2 (de)	1995-08-24	1996-08-23	Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DE69638281T Expired - Lifetime DE69638281D1 (de)	1995-08-24	1996-08-23	Anti-Interleukin-9 Antikörper oder Anti-Interleukin-9 Rezeptor Antikörper zur Behandlung von bronchialem Hyperreaktionsvermögen

Country Status (10)

Country	Link
EP (3)	EP2241329A3 (de)
JP (3)	JP3948495B2 (de)
AT (2)	ATE307203T1 (de)
AU (1)	AU6895696A (de)
CA (2)	CA2230240C (de)
DE (2)	DE69638281D1 (de)
DK (2)	DK1632248T3 (de)
ES (2)	ES2249786T3 (de)
PT (1)	PT1632248E (de)
WO (1)	WO1997008321A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5830454A (en) *	1996-08-30	1998-11-03	Ludwig Institute For Cancer Research	Method for treating cell mediated autoimmune disorders using interleukin-9
CA2689842A1 (en) *	1996-12-02	1998-06-11	Genaera Corporation	Il-9 receptor variants, useful in treating and diagnosing atopic allergies including asthma and related disorders
ES2347962T3 (es) *	1996-12-02	2010-11-26	Ligand Pharmaceuticals Incorporated	Biological variability of asthma associated factor, AAF2 (IL-9 receptor), useful in treating and diagnosing atopic allergies including asthma and related disorders.
AU5532098A (en) *	1996-12-20	1998-07-17	Magainin Pharmaceuticals, Inc.	A method for diagnosis and treatment of inflammatory bowel diseases including crohn's disease and chronic ulcerative colitis
WO1999014242A2 (en) *	1997-09-19	1999-03-25	Magainin Pharmaceuticals Inc.	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
WO1999015656A2 (en) *	1997-09-19	1999-04-01	Magainin Pharmaceuticals Inc.	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
WO2000066708A2 (en) *	1999-05-01	2000-11-09	Magainin Pharmaceuticals, Inc.	Asthma associated factors as targets for treating atopic allergies including asthma and related disorders
WO2001059142A1 (en) *	2000-02-09	2001-08-16	Medimmune, Inc.	Antibody gene therapy with adeno-associated viral vectors
WO2002068594A2 (en) *	2001-02-22	2002-09-06	The Research Foundation Of State University Of New York	Opiate receptors
EP1401497B1 (de)	2001-06-08	2012-01-11	Genaera Corporation	Verfahren zur modulation von il-13
JP2007526208A (ja) *	2003-04-11	2007-09-13	メディミューン，インコーポレーテッド	呼吸器の症状を治療又は予防する方法
US7470521B2 (en)	2004-07-20	2008-12-30	Critical Therapeutics, Inc.	RAGE protein derivatives
US7635754B2 (en) *	2004-09-22	2009-12-22	Aerovance, Inc.	Interleukin-9 and interleukin-4 chimeric antagonist muteins and methods of using same
US8354106B2 (en)	2005-06-16	2013-01-15	The Feinstein Institute For Medical Research	Antibodies against HMGB1 and fragments thereof
WO2008039941A2 (en)	2006-09-27	2008-04-03	The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services	Scgb3a2 as a growth factor and anti-apoptotic agent
JP5564167B2 (ja) *	2008-05-22	2014-07-30	日本たばこ産業株式会社	苦味マスキング剤及び苦味低減方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5208218A (en) *	1988-09-19	1993-05-04	Ludwig Institute For Cancer Research	T cell growth factor glycoproteins
US5414071A (en)	1989-05-23	1995-05-09	Genetics Institute, Inc.	Human cytokine IL-9
US5132109A (en) *	1990-10-05	1992-07-21	Ludwig Institute For Cancer Research	Method for inhibiting production of ige and method for enhancing production of igg using interleukin 9 and inhibitors thereof
CA2186854A1 (en)	1994-03-30	1995-10-12	William J. Alms	Human interleukin variants generated by alternative splicing

1996
- 1996-08-23 EP EP10004496A patent/EP2241329A3/de not_active Withdrawn
- 1996-08-23 CA CA002230240A patent/CA2230240C/en not_active Expired - Lifetime
- 1996-08-23 JP JP51028397A patent/JP3948495B2/ja not_active Expired - Fee Related
- 1996-08-23 EP EP96929657A patent/EP0846173B1/de not_active Expired - Lifetime
- 1996-08-23 WO PCT/US1996/012757 patent/WO1997008321A1/en active IP Right Grant
- 1996-08-23 DE DE69638281T patent/DE69638281D1/de not_active Expired - Lifetime
- 1996-08-23 DK DK05009688.2T patent/DK1632248T3/da active
- 1996-08-23 AU AU68956/96A patent/AU6895696A/en not_active Abandoned
- 1996-08-23 AT AT96929657T patent/ATE307203T1/de active
- 1996-08-23 AT AT05009688T patent/ATE484294T1/de active
- 1996-08-23 DE DE69635305T patent/DE69635305T2/de not_active Expired - Lifetime
- 1996-08-23 ES ES96929657T patent/ES2249786T3/es not_active Expired - Lifetime
- 1996-08-23 PT PT05009688T patent/PT1632248E/pt unknown
- 1996-08-23 ES ES05009688T patent/ES2354360T3/es not_active Expired - Lifetime
- 1996-08-23 CA CA002666298A patent/CA2666298A1/en not_active Abandoned
- 1996-08-23 EP EP05009688A patent/EP1632248B8/de not_active Expired - Lifetime
- 1996-08-23 DK DK96929657T patent/DK0846173T3/da active
2007
- 2007-01-09 JP JP2007001870A patent/JP4813380B2/ja not_active Expired - Fee Related
2011
- 2011-02-28 JP JP2011043283A patent/JP2011152135A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1632248A1 (de)	2006-03-08
JP2007169287A (ja)	2007-07-05
CA2230240A1 (en)	1997-03-06
EP2241329A3 (de)	2011-03-09
JPH11514851A (ja)	1999-12-21
ATE307203T1 (de)	2005-11-15
EP2241329A2 (de)	2010-10-20
EP0846173B1 (de)	2005-10-19
WO1997008321A1 (en)	1997-03-06
JP3948495B2 (ja)	2007-07-25
EP0846173A1 (de)	1998-06-10
PT1632248E (pt)	2010-12-28
EP1632248B8 (de)	2010-12-29
ES2249786T3 (es)	2006-04-01
DK0846173T3 (da)	2006-01-16
JP4813380B2 (ja)	2011-11-09
DE69635305T2 (de)	2006-07-06
DK1632248T3 (da)	2011-01-24
ES2354360T3 (es)	2011-03-14
JP2011152135A (ja)	2011-08-11
EP1632248B1 (de)	2010-10-13
CA2666298A1 (en)	1997-03-06
ATE484294T1 (de)	2010-10-15
DE69638281D1 (de)	2010-11-25
AU6895696A (en)	1997-03-19
CA2230240C (en)	2009-08-18

Publication	Publication Date	Title
DE69635305D1 (de)	2006-03-02	Verwendung eines anti-interleukin-9 antikörpers zur herstellung eines medikamentes zur behandlung von asthma
DE60031396D1 (de)	2006-11-30	Zubereitung zur behandlung von einer neurologischen erkrankung
DE69736183D1 (de)	2006-08-03	Verwendung von topiramat oder derivate davon zur herstellung eines arzneimittels zur behandlung von manisch-depressiven bipolaren störungen
DE69616376D1 (de)	2001-11-29	Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE256475T1 (de)	2004-01-15	Verwendung von follistatin zur herstellung eines arzneimittels zur behandlung von muskuläre krankheiten
DE69600307D1 (de)	1998-06-25	Beatmungsgerät zur Behandlung von Ateminsuffizienzen
ATA76995A (de)	2002-04-15	Stabiles präparat zur behandlung von blutgerinnungsstörungen
DE69022249D1 (de)	1995-10-12	Knochenwachsapplikator zur Behandlung von Knochengewebe.
DE59109222D1 (de)	2001-11-22	Verwendung des Wirkstoffs Flupirtin zur Herstellung eines Arzneimittels zur Bekämpfung von Muskelverspannungen
ATE110265T1 (de)	1994-09-15	Verwendung von sigma-rezeptor-liganden zur herstellung eines anxiolytikums.
ATE137965T1 (de)	1996-06-15	Verwendung von tomoxetine zur behandlung von funktionsstörungen der niedrigen harnwege
ATE246518T1 (de)	2003-08-15	Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
ATE217191T1 (de)	2002-05-15	Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DE69431199D1 (de)	2002-09-26	Melatonin-Derivate zur Verwendung in der Behandlung von Schlafstörungen
DE69729735D1 (de)	2004-08-05	Verwendung von benzopyranolen zur behandlung von neurologischen erkrankungen
ATE294584T1 (de)	2005-05-15	Verwendung von desoxypeganin zur behandlung von alzheimerischer demenz
ATE244008T1 (de)	2003-07-15	Verwendung von makroliden zur behandlung von akuten lungenverletzungen
DE69720064D1 (de)	2003-04-24	Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
DE60034110D1 (de)	2007-05-10	Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
DE69300037D1 (de)	1995-02-09	Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ATE128867T1 (de)	1995-10-15	Verwendung von 3-aryl-5-alkylthio-4h-1,2,4- triazolen zur behandlung von überreflexen infolge von rückenmarkstrauma.
ATE320263T1 (de)	2006-04-15	Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE69926996D1 (de)	2005-10-06	Verwendung von riluzol zur behandlung der retinalischemie
DE69521281D1 (de)	2001-07-19	Verfahren zur Herstellung von menschlichem oder humanem Matrilysin mittels rekombinanter DNA.
DE69632117D1 (de)	2004-05-13	Verwendung von 8,9-Dehydroestron zur Herstellung eines Arzneimittels zur Behandlung von durch freie Radikale verursachte Krankheiten

Legal Events

Date	Code	Title	Description
2006-11-09	8364	No opposition during term of opposition
2010-05-12	8328	Change in the person/name/address of the agent	Representative=s name: GRAF VON STOSCH PATENTANWALTSGESELLSCHAFT MBH, 805
2011-03-31	8327	Change in the person/name/address of the patent owner	Owner name: LIGAND PHARMACEUTICALS INC. (N. D. GES. D. STA, US